natgillin/translations-raw huggingface dataset:
Summary of the safety profile (non-Hodgkin's lymphoma and chronic lymphocytic leukaemia) 
Sažetak sigurnosnog profila (ne-Hodgkinov limfom i kronična limfocitna leukemija)
Cardiac events occurred at a rate of approximately 273 per 100 patient years (95% CI 149-470) at the 6-month primary endpoint. 
Srčani događaji prijavljeni su po stopi od 273 na 100 bolesnik-godina (95 % CI 149-470) u trenutku primarne mjere ishoda nakon 6 mjeseci.
All patients treated with rituximab for rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis must be given the patient alert card with each infusion. 
Svim bolesnicima s reumatoidnim artritisom, granulomatozom s poliangiitisom i mikroskopskim poliangiitisom koji se liječe lijekom rituksimab potrebno je uz svaku infuziju dati karticu s upozorenjima za bolesnika.
When sticking to the surface of this cell, rituximab causes the cell to die. 
Kada se rituksimab veže na površinu te stanice, uzrokuje njezinu smrt.
20 Academy-ro 51 beon-gil 
20 Academy-ro 51 beon-gil Yeonsu-gu, Incheon, 22014, Republika Korea
You will always be given Rituzena as a drip (intravenous infusion). 
Lijek Rituzena ćete uvijek primiti ukapavanjem u venu (intravenskom infuzijom).
Physicians should exercise caution when considering the use of rituximab in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose patients to serious infection (see section 4.8). 
Liječnici trebaju biti oprezni ako razmatraju primjenu lijeka rituksimab u bolesnika s anamnezom rekurentnih ili kroničnih infekcija ili postojećim stanjima koje ih mogu dodatno predisponirati za ozbiljne infekcije (vidjeti dio 4.8).
The chemotherapy should be given after the Rituzena infusion. 
Kemoterapiju treba primijeniti nakon infuzije lijeka Rituzena.
doctor's name and phone number on the dentist you see - not just the specialist 
medicinskoj sestri ili stomatologu koje posjećujete, a ne samo liječniku specijalistu koji Vam propisuje lijek
3infusion related reactions (generalised oedema, 
3reakcije povezane s infuzijom (hipertenzija,
anaphylaxis tumour lysis syndrome, cytokine release syndrome4, serum sickness infusion-relate d acute reversible thrombocytop enia4 
Poremećaji imunološko g sustava anafilaksija sindrom lize tumora, sindrom otpuštanja citokina4, serumska bolest akutna reverzibilna trombocitopenij a povezana s infuzijom4
lung infiltration gastro-intestin al perforation7 
Poremećaji probavnog sustava gastrointestinalna perforacija7
The recommended dosage of Rituzena for induction of remission therapy of granulomatosis with polyangiitis and microscopic polyangiitis is 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks (four infusions in total). 
Preporučena doza lijeka Rituzena za poticanje remisije granulomatoze s poliangiitisom i mikroskopskog poliangiitisa iznosi 375 mg/m2 tjelesne površine primijenjeno intravenskom infuzijom jedanput tjedno tijekom 4 tjedna (ukupno četiri infuzije).
In the relapsed/refractory CLL study grade ¾ thrombocytopenia was reported in 11% of patients in the R-FC group compared to 9% of patients in 
U ispitivanju relapsirajućeg/refraktornog KLL-a trombocitopenija stupnja 3/4 prijavljena je u 11 % bolesnika u skupini koja je primala R-FC u usporedbi s 9 % bolesnika u skupini koja je primala FC.
Repeated treatment courses 
Višestruki ciklusi liječenja
Patients were randomised in a 1:1 ratio to receive either oral cyclophosphamide daily (2mg/kg/day) for 3-6 months or rituximab (375 mg/m2) once weekly for 4 weeks. 
Bolesnici su u omjeru 1:1 randomizirani da primaju ili peroralni ciklofosfamid (2 mg/kg na dan) svakodnevno tijekom 3-6 mjeseci ili rituksimab (375 mg/m2) jedanput tjedno tijekom 4 tjedna.
Corticosteroid medicine given by mouth may be started at any time by your doctor to treat your condition. 
Liječnik Vam za liječenje Vaše bolesti može u bilo kojem trenutku propisati kortikosteroide koji se uzimaju kroz usta.
Excipients: sodium chloride, tri-sodium citrate dihydrate, polysorbate 80, water for injections. 
Pomoćne tvari: natrijev klorid, natrijev citrat, polisorbat 80, voda za injekcije.
Less frequently, some patients may get pain at the infusion site, blisters, itching, sickness, tiredness, headache, breathing difficulties, tongue or throat swelling, itchy or runny nose, vomiting, flushing or palpitations, heart attack or low number of platelets. 
Rjeđe se u nekih bolesnika mogu pojaviti bol na mjestu infuzije, plikovi, svrbež, mučnina, umor, glavobolja, otežano disanje, natečenost jezika ili grla, svrbež ili curenje nosa, povraćanje, navale crvenila ili osjećaj lupanja srca, srčani udar ili malen broj krvnih pločica (trombocita).
The Patient information about Rituzena should contain the following key elements: 
Informacije za bolesnike o lijeku Rituzena moraju sadržavati sljedeće ključne elemente:
PML, reactivation of hepatitis B late neutropenia2 serum sicknesslike reaction 
PML, reaktivacija hepatitisa B
Physicians should exercise caution when considering the use of rituximab in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose patients to serious infection, e.g. hypogammaglobulinaemia (see section 4.8). 
Liječnici trebaju biti oprezni ako razmatraju primjenu lijeka rituksimab u bolesnika s anamnezom rekurentnih ili kroničnih infekcija ili postojećim bolestima koje ih mogu dodatno predisponirati za ozbiljne infekcije, primjerice hipogamaglobulinemijom (vidjeti dio 4.8).
Since hypotension may occur during rituximab infusion, consideration should be given to withholding anti-hypertensive medicinal product 12 hours prior to the rituximab infusion. 
Budući da tijekom infuzije rituksimaba može doći do hipotenzije, treba razmotriti mogućnost izostavljanja antihipertenzivne terapije 12 sati prije primjene infuzije lijeka rituksimab.
System organ class Very common Common 
Organski sustav Vrlo često
The Physician information about Rituzena should contain the following key elements: 
Informacije za liječnike o lijeku Rituzena moraju sadržavati sljedeće ključne elemente:
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given Rituzena. 
Ako se nešto od gore navedenoga odnosi na Vas (ili niste sigurni), obratite se svom liječniku,
Rituzena monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemo-resistant or are in their second or subsequent relapse after chemotherapy. 
Monoterapija lijekom Rituzena indicirana je u liječenju bolesnika oboljelih od folikularnog limfoma stadija III-IV koji su rezistentni na kemoterapiju ili su u drugom odnosno sljedećem relapsu nakon kemoterapije.
Response rate and CR rates analysed using Chi-squared Test. NR: not reached; n.a.: not applicable *: only applicable to patients achieving a CR, nPR, PR **: only applicable to patients achieving a CR 
ND: nije dostignuto; n.p.: nije primjenjivo *: primjenjivo samo za bolesnike koji su postigli CR, nPR ili PR **: primjenjivo samo za bolesnike koji su postigli CR
Units 2100, 2110, 2010, 2120, 2130 and 2500 
Units 2100, 2110, 2010, 2120, 2130 and 2500 Phase 18, Central Park Bridgend Industrial Estate Bridgend, CF31 3TY, UK
Rituzena is provided in sterile, preservative-free, non-pyrogenic, single use vials. 
Rituzena je dostupna u sterilnim, jednokratnim apirogenim bočicama, bez konzervansa.
How much and how often you will receive your treatment If you are being treated for non-Hodgkin's Lymphoma 
Koliko ćete lijeka primiti i koliko često a) Bolesnici koji se liječe od ne-Hodgkinova limfoma ako se liječite samo lijekom Rituzena
This should be followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day, and tapered as rapidly as possible based on clinical need) 
Nakon toga, tijekom i nakon liječenja lijekom Rituzena treba peroralno davati prednizon u dozi od 1 mg/kg na dan (ne više od 80 mg na dan i što brže postupno smanjivati dozu, ovisno o kliničkoj potrebi).
The safety of immunisation with live viral vaccines following rituximab therapy has not been studied. 
Sigurnost cijepljenja živim virusnim cjepivima nakon terapije lijekom rituksimab nije ispitivana.
Serious infections, including fatalities, can occur during therapy with rituximab (see section 4.8).Rituximab should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3) or severely immunocompromised patients (e.g. where levels of CD4 or CD8 are very low). 
Rituksimab se ne smije primijeniti bolesnicima s aktivnom teškom infekcijom (npr. tuberkulozom, sepsom i oportunističkim infekcijama, vidjeti dio 4.3) ili teško imunokompromitiranim bolesnicima (npr. kada su razine CD4 ili CD8 stanica vrlo niske).
In placebo-controlled periods of clinical trials, 0.94% (13/1382) of rituximab treated patients and 
U placebom kontroliranim razdobljima kliničkih ispitivanja u 0,94 % (13/1382) bolesnika liječenih rituksimabom te 0,27 % (2/731) bolesnika koji su primali placebo razvila se teška neutropenija.
The most common symptoms were allergic reactions like headache, pruritus, throat irritation, flushing, rash, urticaria, hypertension, and pyrexia. 
Najčešći simptomi bile su alergijske reakcije, kao što su glavobolja, svrbež, iritacija grla, navale crvenila, osip, urtikarija,
CLL affects B-lymphocytes, which originate in the bone marrow and develop in the lymph nodes. 
Kronična limfocitna leukemija zahvaća B-limfocite, koji nastaju u koštanoj srži, a razvijaju se u limfnim čvorovima.
Table 2 Summary of adverse drug reactions reported in clinical trials or during post marketing surveillance occurring in patients with rheumatoid arthritis receiving 
Tablica 2 Sažetak nuspojava prijavljenih u kliničkim ispitivanjima ili nakon stavljanja lijeka u promet u bolesnika s reumatoidnim artritisom koji su primali rituksimab
These symptoms are usually reversible with interruption of rituximab infusion and administration of an anti-pyretic, an antihistaminic, and, occasionally, oxygen, intravenous saline or bronchodilators, and glucocorticoids if required. 
Ti se simptomi obično povlače nakon prekida infuzije rituksimaba i primjene antipiretika, antihistaminika te ponekad kisika, intravenske primjene fiziološke otopine ili bronhodilatatora te po potrebi glukokortikoida.
Since hypotension may occur during rituximab administration, consideration should be given to withholding anti-hypertensive medicines 12 hours prior to the rituximab infusion. 
S obzirom da tijekom primjene lijeka rituksimab može doći do hipotenzije, potrebno je razmotriti mogućnost izostavljanja antihipertenzivne terapije 12 sati prije davanja infuzije lijeka rituksimab.
The recommended dosage of Rituzena in combination with chemotherapy for previously untreated and relapsed/refractory patients is 375 mg/m2 body surface area administered on day 0 of the first treatment cycle followed by 500 mg/m2 body surface area administered on day 1 of each subsequent cycle for 6 cycles in total. 
Preporučena doza lijeka Rituzena u kombinaciji s kemoterapijom za prethodno neliječene bolesnike i bolesnike koji nisu odgovorili na liječenje ili su u relapsu iznosi 375 mg/m2 tjelesne površine primijenjeno nultog dana prvog ciklusa liječenja, nakon čega slijedi 500 mg/m2 tjelesne površine primijenjeno prvog dana svakog sljedećeg ciklusa, tijekom ukupno 6 ciklusa.
What Rituzena is and what it is used for What you need to know before you use Rituzena 
Što je Rituzena i za što se koristi Što je Rituzena
Mean terminal elimination half-life after the second infusion, following the second course, was 19 days for 2 x 500 mg dose and ranged from 21 to 22 days for the 2 x 1000 mg dose. 
Srednje terminalno poluvrijeme eliminacije nakon druge infuzije i drugog ciklusa iznosilo je 19 dana za dozu od 2 x 500 mg te od 21 do 22 dana za dozu od 2 x 1000 mg.
The difference between the treatment groups with respect to overall survival showed a significant clinical difference (p=0.029, log-rank test stratified by centre): survival rates at 53 months were 80.9% for patients in the R-CVP group compared to 71.1 % for patients in the CVP group． 
log-rang test stratificiran prema centru): stope preživljenja nakon 53 mjeseca bile su 80,9 % za bolesnike u R-CVP skupini, u usporedbi sa 71,1 % za bolesnike u CVP skupini.
The Patient Alert Card for Rituzena in non-oncology indications should contain the following key 
Kartica s upozorenjima za bolesnika za lijek Rituzena u neonkološkim indikacijama mora sadržavati sljedeće ključne elemente:
Therefore vaccination with live virus vaccines is not recommended whilst on rituximab or whilst peripherally B cell depleted. 
Stoga se ne preporučuje cijepljenje živim virusnim cjepivima za vrijeme primjene lijeka rituksimab odnosno dok je prisutna deplecija B-stanica u perifernoj krvi.
Patients in both arms received 1000mg of pulse intravenous (IV) methylprednisolone (or another equivalent-dose glucocorticoid) per day for 1 to 3 days, followed by oral prednisone (1 mg/kg/day, not exceeding 80 mg/day). 
Bolesnici u obje skupine su tijekom 1 do 3 dana primali pulsnu intravensku (i.v.) terapiju metilprednizolonom u dozi od 1000 mg na dan (ili drugi glukokortikoid u ekvivalentnoj dozi), a zatim peroralni prednizon (1 mg/kg na dan, ali ne više od 80 mg na dan).
The complete response rate after cycle 8 was 76.2 % in the R-CHOP group and 62.4 % in the CHOP 
Nakon 24 mjeseca procjene ukupnog preživljenja iznosile su 68,2 % za R-CHOP skupinu, odnosno 57,4 % za CHOP skupinu.
95.1%b CI (−3.2%, 24.3%) a a Non-inferiority was demonstrated since the lower bound (−3.2%) was higher than the pre-determined b The 95.1% confidence level reflects an additional 0.001 alpha to account for an interim efficacy analysis. 
b Razina pouzdanosti od 95,1 % odražava dodatni alfa od 0,001 koji uzima u obzir privremenu analizu djelotvornosti.
The pharmacokinetic (PK) parameters in the anti-TNF inadequate responder population, following the same dosage regimen (2 x 1000 mg, IV, 2 weeks apart), were similar with a mean maximum serum concentration of 369 µg/mL and a mean terminal half-life of 19.2 days. 
inhibitorom su uz isti režim doziranja (2 x 1000 mg, intravenski, u razmaku od dva tjedna) bili slični, uz prosječnu najvišu koncentraciju u serumu od 369 µg/ml i srednji terminalni poluvijek od 19,2 dana.
OS rates - survival rates at the time of the analyses 
stope OS - stope preživljenja u trenutku analize (engl.
PATIENT ALERT CARD TEXT FOR NON-ONCOLOGY INDICATIONS Rituzena Alert Card for patients with non-oncology diseases 
Rituzena kartica s upozorenjima za bolesnike s neonkološkim bolestima
There are no data on the safety of rituximab in patients with moderate heart failure (NYHA class III) or severe, uncontrolled cardiovascular disease. 
Nema podataka o sigurnosti lijeka rituksimab u bolesnika s umjerenim zatajenjem srca (NYHA
It is recommended that immunoglobulin levels are determined prior to initiating treatment with rituximab. 
Preporučuje se prije početka liječenja lijekom rituksimab odrediti razine imunoglobulina.
The incidence of infusion-related symptoms decreases substantially with subsequent infusions and is less than 1% after 
Incidencija simptoma povezanih s infuzijom znatno se smanjuje u sljedećim infuzijama te nakon osam doza rituksimaba iznosi manje od 1 %.
See section 4. 
Tablica 7.
• The need to check, prior to Rituzena treatment, for infections, for immunosuppression, for prior/current medication affecting the immune system and recent history of, or planned, 
imunosupresiju, prethodnu/trenutačnu primjenu lijekova koji djeluju na imunološki sustav te nedavna ili planirana cijepljenja.
The most common IRRs included cytokine release syndrome, flushing, throat irritation, and tremor. 
Najčešće infuzijske reakcije bile su sindrom otpuštanja citokina, navale crvenila, iritacija grla i tremor.
Rituzena was administered on the first day of the 
Rituzena je primijenjena prvog dana ciklusa liječenja.
This includes rheumatoid arthritis and off-label autoimmune diseases, including Systemic Lupus Erythematosus (SLE) and 
To uključuje primjenu u reumatoidnom artritisu i neodobrenim indikacijama za liječenje autoimunih bolesti kao što su sistemski lupus eritematodes i vaskulitis.
The most frequent ADRs following receipt of rituximab in clinical studies were IRRs. 
Najčešće nuspojave nakon primitka rituksimaba u kliničkim ispitivanjima bile su reakcije povezane s infuzijom.
Contraindications for use in rheumatoid arthritis, granulomatosis with polyangiitis and microscopic 
Kontraindikacije za primjenu kod reumatoidnog artritisa, granulomatoze s poliangiitisom i mikroskopskog poliangiitisa
Rituzena is used for inducing remission in granulomatosis with polyangiitis (formerly called Wegener's granulomatosis) or microscopic polyangiitis, taken in combination with corticosteroids. 
Rituzena se u kombinaciji s kortikosteroidima primjenjuje za poticanje remisije granulomatoze s poliangiitisom (ranije se zvala Wegenerova granulomatoza) i mikroskopskog poliangiitisa.
Summary of the Safety Profile (granulomatosis with polyangiitis and microscopic polyangiitis) In the clinical trial in granulomatosis with polyangiitis and microscopic polyangitis, 99 patients were treated with rituximab (375 mg/m2, once weekly for 4 weeks) and glucocorticoids (see section 5.1). 
U kliničkom ispitivanju kod granulomatoze s poliangiitisom i mikroskopskog poliangiitisa 99 bolesnika je liječeno rituksimabom (375 mg/m2, jedanput tjedno tijekom 4 tjedna) i glukokortikoidima (vidjeti dio 5.1).
Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients listed in 
Preosjetljivost na djelatnu tvar, mišje proteine ili neku od ostalih pomoćnih tvari navedenih u dijelu 6.1.
• The need to monitor patients for infections, especially PML, during and after 
• Bolesnike je potrebno nadzirati zbog mogućeg razvoja infekcija, osobito PML-a, tijekom i nakon liječenja lijekom Rituzena.
In all patients subgroups (gender, age, age adjusted IPI, Ann Arbor stage, ECOG, β2 
IPI), Ann Arbor stadij, ECOG (engl.
The effect of multiple rituximab courses on the development of neutropenia in granulomatosis with polyangiitis and microscopic polyangiitis patients has not been 
Učinak višestrukih ciklusa rituksimaba na razvoj neutropenije u bolesnika s granulomatozom s poliangiitisom i mikroskopskim poliangiitisom nije ispitivan u kliničkim ispitivanjima.
SUBSTANCE AND MANUFACTURERS RESPONSIBLE CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OTHER CONDITIONS AND REQUIREMENTS OF THE CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL 
ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET B. UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I PRIMJENU C. OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE LIJEKA U
Your doctor will check if you should have any vaccines 
Vaš će liječnik provjeriti morate li primiti neko cjepivo prije nego što primite lijek Rituzena.
dysgeusia peripheral neuropathy, facial nerve cranial neuropathy, loss of other 
kranijalna neuropatija, gubitak drugih osjeta5
Hepatitis B virus (HBV) screening should be performed in all patients before initiation of treatment with rituximab. 
Sve bolesnike mora se prije početka liječenja lijekom rituksimab testirati na virus hepatitisa B (HBV).
Mean terminal elimination half-life ranged from 15 to 16 days for the 2 x 500 mg dose group and 17 to 21 days for the 2 x 1000 mg dose group. 
Srednje terminalno poluvrijeme eliminacije iznosilo je od 15 do 16 dana u skupini koja je primala dozu od 2 x 500 mg te 17 do 21 dan u skupini koja je primala dozu od 2 x 1000 mg.
Following second infusion, mean Cmax ranged from 183 to 198 µg/mL for the2 x 500 mg dose and ranged from 355 to 404 µg/mL for the 2 x 1000 mg dose. 
Nakon druge se infuzije prosječni Cmax kretao između 183 i 198 µg/ml pri dozi od 2 x 500 mg, odnosno između 355 i 404 µg/ml pri dozi od 2 x 1000 mg.
Efficacy was observed both for patients with newly diagnosed disease and for patients with relapsing 
Djelotvornost je opažena i u bolesnika s novodijagnosticiranom bolešću i u bolesnika s relapsirajućom bolešću (Tablica 8).
Table 8 Complete remission at 6-months by disease status Cyclophosphamide Difference (CI 95%) 
Potpuna remisija nakon 6 mjeseci prema statusu bolesti Ciklofosfamid
You must also do this for 12 months after your last treatment with Rituzena. 
Morate to činiti i još 12 mjeseci nakon posljednje primjene lijeka
microglobulin, LDH, albumin, B symptoms, bulky disease, extranodal sites, bone marrow involvement), the risk ratios for event-free survival and overall survival (R-CHOP compared with CHOP) were less than 0.83 and 0.95 respectively. 
ekstranodalna sijela, zahvaćenost koštane srži) omjer rizika za preživljenje bez događaja (R-CHOP u odnosu na CHOP) bio je manji od 0,83, a za ukupno preživljenje manji od 0,95.
Patients who have ever had hepatitis B infection will be carefully checked by their doctor for 
Liječnik će pažljivo nadzirati bolesnike koji su imali infekciju virusom hepatitisa B kako bi uočio moguće znakove infekcije.
The median duration of response was 37.7 months in the R-CVP group and was 13.5 months in the CVP group (p < 
Medijan odgovora iznosio je 37,7 mjeseci u skupini liječenoj R-CVP-om i 13,5 mjeseci u skupini liječenoj CVP-om (p < 0,0001, log-rang test).
c) Granulomatosis with polyangiitis or microscopic polyangiitis 
c) granulomatoze s poliangiitisom ili mikroskopskog poliangiitisa
Table 5b First-line treatment of chronic lymphocytic leukaemia Hazard ratios of progression-free survival according to Binet stage (ITT) - 48.1 months median observation time Number of patients 
Omjeri hazarda za preživljenje bez progresije bolesti prema Binetovom stadiju (ITT populacija) - medijan vremena promatranja je 48,1 mjesec Preživljenje bez progresije bolesti (PFS)
The consequences of long term B cell depletion in paediatric 
Posljedice dugotrajne deplecije B stanica u pedijatrijskih bolesnika nisu poznate.
At 24 months, estimates for overall survival were 68.2 % in the R-CHOP arm compared to 57.4 % in the CHOP arm. A subsequent analysis of the duration of overall survival, carried out with a median follow-up duration of 60 months, confirmed the benefit of R-CHOP over CHOP treatment (p=0.0071), representing a risk reduction of 32 %. 
Kasnija analiza trajanja ukupnog preživljenja, provedena nakon medijana praćenja od 60 mjeseci, potvrdila je prednost liječenja R-CHOP-om u odnosu na liječenje CHOP-om (p = 0,0071), što predstavlja smanjenje rizika za 32 %.
Pack of 2 
2 bočice
Rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis 
Reumatoidni artritis, granulomatoza s poliangiitisom i mikroskopski poliangiitis
For the 60 re-treatments on study, the ORR was 38% (CI95 % 26% - 51%; 10% CR, 28% PR) with a projected median TTP for responding patients of 17.8 months (range 5.4 - 26.6). 
26 % - 51 %; CR 10 %, PR 28 %), a procijenjeni medijan TTP-a u bolesnika koji su odgovorili na liječenje 17,8 mjeseci (raspon 5,4-26,6 mjeseci).
In most cases, the infusion can be resumed at a 50 % reduction in rate (e.g. from 100 mg/h to 50 mg/h) when symptoms have completely 
100 mg/sat na 50 mg/sat) kada se simptomi u potpunosti povuku.
severe bullous skin reactions, Stevens-Johns on Syndrome toxic epidermal necrolysis (Lyell's Syndrome)7, 
Poremećaji kože i potkožnog tkiva toksična epidermalna nekroliza (Lyellov sindrom), StevensJohnsonov sindrom5
The trial demonstrated non-inferiority of rituximab to cyclophosphamide for complete remission 
Ispitivanje je pokazalo neinferiornost rituksimaba u odnosu na ciklofosfamid u postizanju potpune remisije nakon 6 mjeseci (Tablica 7).
The available data indicate that the rate of clinically relevant infection is unchanged when such therapies are used in patients previously treated with rituximab, however patients should be closely observed for signs of infection if biologic agents and/or DMARDs are used following rituximab 
Dostupni podaci pokazuju da je stopa klinički značajnih infekcija nepromijenjena kada se ti lijekovi primjenjuju u bolesnika koji su prethodno liječeni rituksimabom.